Journal
MEDICAL ONCOLOGY
Volume 24, Issue 1, Pages 71-75Publisher
HUMANA PRESS INC
DOI: 10.1007/BF02685905
Keywords
gastric cancer; chemotherapy; taxan; docetaxcel; 5'DFUR; second-line chemotherapy
Categories
Ask authors/readers for more resources
We conducted a clinical pilot study to evaluate the efficacy and safety of the combination of docetaxel and 5'DFUR as a second-line chemotherapy for gastric cancer. Twenty-four patients were divided into two groups by simple randomization: group A (60 mg/m(2) of docetaxel, every 3 wk) and group B (regimen A + 600 mg/body of 5'DFUR). The response rate was 17% and 42% in group A and B, respectively (p < 0.05). The MST from the start of the first-line was 17 mo in group B. The major adverse event was leukopenia in both groups.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available